Literature DB >> 10666370

Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.

R Baffa1, L G Gomella, A Vecchione, P Bassi, K Mimori, J Sedor, C M Calviello, M Gardiman, C Minimo, S E Strup, P A McCue, A J Kovatich, F Pagano, K Huebner, C M Croce.   

Abstract

Cytogenetic and loss of heterozygosity (LOH) studies demonstrated chromosome 3p deletions in transitional cell carcinoma (TCC). We recently cloned the tumor suppressor gene FHIT (fragile histidine triad) at 3p14.2, one of the most frequently deleted chromosomal regions in TCC of the bladder, and showed that it is the target of environmental carcinogens. Abnormalities at the FHIT locus have been found in tumors of the lung, breast, cervix, head and neck, stomach, pancreas, and clear cell carcinoma of the kidney. We examined six TCC derived cell lines (SW780, T24, Hs228T, CRL7930, CRL7833, and HTB9) and 30 primary TCC of the bladder for the integrity of the FHIT transcript, using reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate a potential role of the FHIT gene in TCC of the bladder. In addition, we tested expression of the Fhit protein in the six TCC-derived cell lines by Western blot analysis and in 85 specimens of primary TCCs by immunohistochemistry. Three of the six cell lines (50%) did not show the wild-type FHIT transcript, and Fhit protein was not detected in four of the six cell lines (67%) tested. Fhit expression also was correlated with pathological and clinical status. A significant correlation was observed between reduced Fhit expression and advanced stage of the tumors. Overall, 26 of 30 (87%) primary TCCs showed abnormal transcripts. Fhit protein was absent or greatly reduced in 61% of the TCCs analyzed by immunohistochemistry. These results suggested that loss of Fhit expression may be as important in the development of bladder cancer as it is for other neoplasms caused by environmental carcinogens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666370      PMCID: PMC1850046          DOI: 10.1016/S0002-9440(10)64745-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites.

Authors:  C M Wilke; B K Hall; A Hoge; W Paradee; D I Smith; T W Glover
Journal:  Hum Mol Genet       Date:  1996-02       Impact factor: 6.150

2.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

3.  The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.

Authors:  C Sorio; A Baron; S Orlandini; G Zamboni; P Pederzoli; K Huebner; A Scarpa
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

Review 4.  Bladder cancer epidemiology and pathogenesis.

Authors:  R K Ross; P A Jones; M C Yu
Journal:  Semin Oncol       Date:  1996-10       Impact factor: 4.929

Review 5.  Current management of invasive and metastatic transitional cell carcinoma of the bladder.

Authors:  J B Thrasher; E D Crawford
Journal:  J Urol       Date:  1993-05       Impact factor: 7.450

6.  Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines.

Authors:  K Yanagisawa; M Kondo; H Osada; K Uchida; K Takagi; A Masuda; T Takahashi; T Takahashi
Journal:  Cancer Res       Date:  1996-12-15       Impact factor: 12.701

7.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions.

Authors:  G Sozzi; U Pastorino; L Moiraghi; E Tagliabue; F Pezzella; C Ghirelli; S Tornielli; L Sard; K Huebner; M A Pierotti; C M Croce; S Pilotti
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma.

Authors:  P Cairns; A J Proctor; M A Knowles
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

9.  Role of chromosome 9 in human bladder cancer.

Authors:  N Miyao; Y C Tsai; S P Lerner; A F Olumi; C H Spruck; M Gonzalez-Zulueta; P W Nichols; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

10.  Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase.

Authors:  L D Barnes; P N Garrison; Z Siprashvili; A Guranowski; A K Robinson; S W Ingram; C M Croce; M Ohta; K Huebner
Journal:  Biochemistry       Date:  1996-09-10       Impact factor: 3.162

View more
  12 in total

1.  Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit.

Authors:  T Shiraishi; T Druck; K Mimori; J Flomenberg; L Berk; H Alder; W Miller; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 2.  Biomarkers for bladder cancer management: present and future.

Authors:  Fei Ye; Li Wang; Mireia Castillo-Martin; Russell McBride; Matthew D Galsky; Jun Zhu; Paolo Boffetta; David Y Zhang; Carlos Cordon-Cardo
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

3.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines.

Authors:  Luca Roz; Marcella Gramegna; Hideshi Ishii; Carlo M Croce; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 4.  Common fragile site tumor suppressor genes and corresponding mouse models of cancer.

Authors:  Alessandra Drusco; Yuri Pekarsky; Stefan Costinean; Anna Antenucci; Laura Conti; Stefano Volinia; Rami I Aqeilan; Kay Huebner; Nicola Zanesi
Journal:  J Biomed Biotechnol       Date:  2010-12-29

5.  Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma.

Authors:  Kim Vaiphei; Aruna Rangan; Rajinder Singh
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

6.  Reduced Fhit protein expression in human malignant mesothelioma.

Authors:  Lea Pylkkänen; Henrik Wolff; Tuula Stjernvall; Aija Knuuttila; Sisko Anttila; Kirsti Husgafvel-Pursiainen
Journal:  Virchows Arch       Date:  2003-10-16       Impact factor: 4.064

7.  Oncosuppressor proteins of fragile sites are reduced in cervical cancer.

Authors:  Enrico Giarnieri; Nicola Zanesi; Arianna Bottoni; Mauro Alderisio; Ankica Lukic; Aldo Vecchione; Vincenzo Ziparo; Carlo Maria Croce; Rita Mancini
Journal:  Cancer Lett       Date:  2009-08-22       Impact factor: 8.679

Review 8.  Fragile histidine triad protein: structure, function, and its association with tumorogenesis.

Authors:  Md Imtaiyaz Hassan; Abdullah Naiyer; Faizan Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-24       Impact factor: 4.553

9.  Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.

Authors:  Andrea Vecchione; Tommaso Prayer Galetti; Marina Gardiman; Hideshi Ishii; Enrico Giarnieri; Francesco Pagano; Leonard G Gomella; Carlo M Croce; Raffaele Baffa
Journal:  BMC Urol       Date:  2004-09-09       Impact factor: 2.264

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.